Study drug plus docetaxel and abiraterone for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed by biopsy/pathology (or a pathology report plus medical history that fits prostate cancer).
- Your cancer has spread to other parts of the body (metastatic disease), shown on a bone scan or on CT scans.
- If your cancer is mCSPC (still responds to hormone therapy): you must start ADT within 134 days (and for one part of the study, you may need “high-volume” spread).
- If your cancer is mCRPC (no longer responds to hormone therapy): you need ongoing ADT, have had newer hormone-blocking pills (like abiraterone/enzalutamide/apalutamide/darolutamide), and should not have progressed on docetaxel (or within 3 months of finishing it for mCSPC).
- You must be able to have the required blood tests and organ function (bone marrow, liver, kidneys) and have an overall health status that’s not too poor (ECOG 0–2).
- You must be willing to sign consent, have follow-up visits (including traveling to NIH), and use effective contraception during treatment and for several months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
This trial tests a combination of two drugs (darolutamide plus hormone therapy) along with a low dose of chemotherapy (docetaxel) for men whose prostate cancer has spread to other parts of the body. It aims to see if this combined approach is safe and effective.
This trial tests a new drug called dalpiciclib combined with standard hormone therapy (abiraterone and prednisone) for men with prostate cancer that has spread and is hormone-sensitive. The goal is to see if adding the new drug helps control the cancer better than the standard treatment alone.
This study tests a new investigational medicine for prostate cancer that has spread and is no longer controlled by standard hormone therapy. The drug may work by targeting a protein on cancer cells, and the trial will check if it can shrink the cancer or slow its growth.
This trial tests a combination of two drugs—disitamab vedotin (a targeted antibody-drug that attacks HER2-positive cancer cells) and abiraterone (a hormone therapy)—to see if they can slow or shrink prostate cancer that has spread and become resistant to standard treatments.
Hear when a new Cancer Of Prostate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.